The novel class of GLP-1 receptor and GIP co-agonist medications, such as tirzepatide, semaglutide, and the recently introduced retatrutide, represent promising progress in metabolic management . Despite https://hplcpeptidetesting830718.collectblogs.com/88429485/retatrutide-the-detailed-review